Becton, Dickinson and Company $BDX Stock Position Raised by Gries Financial LLC

Key Points

• Gries Financial LLC significantly increased its stake in Becton, Dickinson and Company by 118.4%, owning 7,666 shares worth approximately $1.32 million at the end of the second quarter.
• The company has announced a quarterly dividend of $1.04 per share, which signifies a 2.2% yield, with the ex-dividend date set for September 8th.
• Becton, Dickinson reported $3.68 EPS for the last quarter, exceeding analysts' expectations of $3.40, and anticipates earnings of 14.43 per share for the current fiscal year.

Gries Financial LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 118.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,666 shares of the medical instruments supplier's stock after buying an additional 4,156 shares during the quarter. Gries Financial LLC's holdings in Becton, Dickinson and Company were worth $1,320,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BDX. Brighton Jones LLC lifted its position in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares in the last quarter. Hara Capital LLC lifted its position in Becton, Dickinson and Company by 26.4% in the 4th quarter. Hara Capital LLC now owns 335 shares of the medical instruments supplier's stock worth $76,000 after buying an additional 70 shares in the last quarter. Vise Technologies Inc. purchased a new stake in Becton, Dickinson and Company in the 4th quarter worth approximately $361,000. GTS Securities LLC lifted its position in Becton, Dickinson and Company by 108.9% in the 4th quarter. GTS Securities LLC now owns 1,344 shares of the medical instruments supplier's stock worth $305,000 after buying an additional 16,410 shares in the last quarter. Finally, Toronto Dominion Bank lifted its position in Becton, Dickinson and Company by 7.2% in the 4th quarter. Toronto Dominion Bank now owns 160,305 shares of the medical instruments supplier's stock worth $36,367,000 after buying an additional 10,719 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of the firm's stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of the firm's stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director owned 22,226 shares of the company's stock, valued at $4,167,375. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 2,965 shares of company stock valued at $551,536 in the last 90 days. Corporate insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $186.74 on Tuesday. The company has a 50-day moving average of $187.84 and a 200-day moving average of $189.61. The company has a market capitalization of $53.53 billion, a price-to-earnings ratio of 33.59, a PEG ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The company had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same period last year, the firm earned $3.50 EPS. The firm's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Investors of record on Monday, September 8th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Wall Street Analyst Weigh In

Several brokerages have recently commented on BDX. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Barclays dropped their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 3rd. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $213.30.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.